Mink therapeutics to participate in b. riley securities oncology conference

New york, jan. 11, 2023 (globe newswire) -- mink therapeutics, inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, announced that dr. jennifer buell, president and ceo of mink, will participate in a fireside chat at the 3rd annual b. riley securities oncology conference on january 18th, at 11:00 am et.
INKT Ratings Summary
INKT Quant Ranking